Welcome to the latest edition of the Cambridge Early Phase Clinical Trials Team newsletter, which outlines our current portfolio available at Addenbrooke's Hospital and ongoing developments in early phase clinical trial activity. Please feel free to contact our team if you wish to participate or discuss a potentially suitable patient.

**New developments**

**Exciting new collaborations with AstraZeneca**

The early phase team are delighted to be leading new collaborations with AstraZeneca. The collaborations will proceed soon and are a prelude to AstraZeneca's relocation of their UK-based research and development centre and corporate headquarters to the Cambridge Biomedical Campus. The projects involve:

- monitoring circulating tumour DNA in tumour response, progression and resistance
- studying the combination of olaparib (PARP inhibitor) and AZD2014 (MTOR inhibitor) in patients with high-risk prostate cancer
- pre-clinical evaluation of novel therapeutic approaches for pancreatic cancer.

**Shionogi S222611 (EGFR/HER2 inhibitor) phase I study presented at ASCO 2012**

S-222611 was well tolerated and a substantial proportion of patients with HER2 or EGFR expressing tumours showed tumour responses or disease stabilisation including a complete response in a patient with HER2-positive breast cancer [Abstract #3100].

**Amendment to increase recruitment to HYPAZ**

This phase IIb study of pazopanib is designed to identify the causative mechanism behind hypertension that develops in patients treated with anti-angiogenics. Eligibility for this all-comers study has been amended so that patients who have received prior anti-angiogenic or tyrosine kinase inhibitor agents are now able to participate (with a washout period of 12 weeks). In addition patients with diabetes are now eligible. Exclusion criteria still include hypertension and the presence of endobronchial lesions.

**The Early Phase Trials Team — coming to your Centre soon!**

We are planning a series of roadshows around the region to introduce ourselves and highlight the early phase studies available at Addenbrooke’s. We would be very interested in your views on how we can optimise patient access to experimental cancer therapy trials in your area.
CURRENT TRIALS IN PROGRESS

“HYPAZ” — pazopanib
Study of the mechanisms of pazopanib-induced hypertension in various tumour types

“VANSEL” — Vandetanib + Selumetinib
Patients with non-small cell lung cancer who have received prior EGFR-targeted therapies

Shionogi S222611 — EGFR/HER2 inhibitor
Patients with EGFR+ or HER2+ gastric cancer, or EGFR+ or HER2+ breast cancer with stable brain metastases

“NOTCH” — Gemcitabine + MK0752
Addition of gamma secretase inhibitor for first-line treatment of pancreatic cancer

“RADICAL” — AZD4547 + Aromatase inhibitor
FGFR1 inhibitor for patients with ER+ metastatic breast cancer who have progressed on anastrazole or letrozole

“OPARATIC” — Olaparib + temozolomide
Addition of PARP inhibitor for patients with relapsed glioblastoma (GBM) for palliative resection

Immunocore IMCgp100
T-cell receptor stimulating peptide in advanced melanoma

AT13387 + abiraterone
HSP90 inhibitor for patients with advanced prostate cancer no longer responding to abiraterone

“TOTEM” — Temsirolimus + gemcitabine and cisplatin
Combining mTOR inhibitor with chemotherapy for advanced urothelial cancers

C28001
Pan-RAF inhibitor in NRAS or BRAF mutant melanoma

Upcoming Trials

These Early Phase studies are opening in the near future — Please bear them in mind!

“TAX-TORC”: Addition of TORC1/2 inhibitor to weekly paclitaxel for ovarian, breast and lung cancers

“Carboplatin + SGI-110”: Addition of DNA methylation inhibitor in platinum resistant ovarian cancer

“PAKT study”: Weekly paclitaxel + AZD5363 (AKT inhibitor) for triple negative breast cancer

“BASALT3”: PI3 kinase inhibitor + docetaxel in 2nd line squamous cell lung cancer

“PISARRO”: Mutant p53 modulator (APR246) + chemotherapy (carboplatin and liposomal doxorubicin) in platinum-sensitive high grade serous ovarian cancer